These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8995557

  • 21. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 22. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S.
    Anticancer Res; 2005 Aug; 25(5):3501-5. PubMed ID: 16101169
    [Abstract] [Full Text] [Related]

  • 23. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
    Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E.
    Gynecol Oncol; 1999 Jan; 72(1):60-4. PubMed ID: 9889031
    [Abstract] [Full Text] [Related]

  • 24. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K.
    Anticancer Res; 2002 Jan; 22(3):1833-8. PubMed ID: 12168878
    [Abstract] [Full Text] [Related]

  • 25. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 26. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Chemotherapy of advanced ovarian cancer.
    Martoni A, Cacciari N, Angelelli B, Zamagni C, Pannuti F.
    Front Biosci; 1997 Mar 15; 2():g20-6. PubMed ID: 9159262
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP, Straughn JM, Leath CA, Kilgore LC, Huh WK, Barnes MN, Partridge EE, Alvarez RD.
    Oncologist; 2006 Apr 15; 11(4):336-41. PubMed ID: 16614229
    [Abstract] [Full Text] [Related]

  • 32. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A, Crespo C, García-López JL, Pedraza M, Garrido P, Lastra E, Moyano A.
    Gynecol Oncol; 2002 Mar 15; 84(3):368-73. PubMed ID: 11855871
    [Abstract] [Full Text] [Related]

  • 33. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [Abstract] [Full Text] [Related]

  • 34. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Köhler G, Diergarten K.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [Abstract] [Full Text] [Related]

  • 35. Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience.
    Kudelka AP, Tresukosol D, Gonzalez de Leon C, Termrungruanglert W, Edwards CL, Freedman RS, Tornos C, Kavanagh JJ.
    J Med Assoc Thai; 1996 Apr 15; 79(4):240-5. PubMed ID: 8708510
    [Abstract] [Full Text] [Related]

  • 36. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R, Steiner M, Atad J, Sneiderman B, Rosenberg T, Palti S.
    Harefuah; 1998 Apr 15; 134(8):605-8, 671. PubMed ID: 10911422
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Taxol in epithelial ovarian cancer.
    Caldas C, McGuire WP.
    J Natl Cancer Inst Monogr; 1993 Apr 15; (15):155-9. PubMed ID: 7517152
    [Abstract] [Full Text] [Related]

  • 39. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R, Vorlicek J, Slavik M.
    Neoplasma; 1996 Apr 15; 43(3):141-54. PubMed ID: 8841500
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.